Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.
Using participant skin cells reprogrammed into neurons, Weill Cornell Medicine researchers have identified genetic signatures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results